CSIMarket
 


Royalty Pharma Plc  (RPRX)
Other Ticker:  
 


Royalty Pharma Plc's EBITDA Margin by quarter

Trends, Rankings, Statistics



RPRX EBITDA Margin (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Revenue Change 5.36 % -6.48 % 0.42 % 21.69 % -1.73 %
Seq. Revenue Change 11.14 % -0.35 % -21.31 % 20.9 % -1.35 %
Revenue In Millions $596.07 $536.31 $538.20 $683.97 $565.75
EBITDA Margin - 31.35 % 74 % 81.3 % -99.53 %
EBITDA Margin Total Ranking # 102 # 1019 # 419 # 292 #
EBITDA In Millions $764.84 $168.11 $398.29 $556.04 $-563.08
Y / Y EBITDA Change - -37.13 % -26.05 % 217.47 % -
Seq. EBITDA Change - -57.79 % -28.37 % - -


Commenting fourth Quarter 2023 EBITDA Margin
Royalty Pharma Plc EBITDA grew by 354.96 % in IV. Quarter sequentially to 765 millions, while Revenue increased by 11.14 %, this led to improvement in the company's EBITDA Margin to 128.31 %, EBITDA Margin remained below Royalty Pharma Plc average.

Observing fourth quarter 2023 results within Major Pharmaceutical Preparations industry 6 other companies have achieved higher EBITDA Margin. While EBITDA Margin total ranking has impoved so far to 102, from total ranking in previous quarter at 1019.
Learn about Operating Margin
RPRX's EBITDA Margin fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 7
Healthcare Sector # 10
Overall # 102

EBITDA Margin Statistics
High Average Low
557833.33 % 37258.35 % 17.48 %
(Dec 31 2014)   (Dec 31 2021)




Other EBITDA Margin Profitability Ratios
RPRX's Cumulative EBITDA Margin
Major Pharmaceutical Preparations Industry EBITDA Margin Trends and Statistics
Healthcare Sector EBITDA Margin Statistics
EBITDA Margin Profitability Trends for overall market
RPRX's EBITDA Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking EBITDA Margin
Lowest Ranking EBITDA Margin
EBITDA Margin Profit Margin for RPRX's Competitors
EBITDA Margin Profit Margin for Royalty Pharma Plc's Suppliers
EBITDA Margin Profit Margin for RPRX's Customers

You may also want to know
RPRX's Annual Growth Rates RPRX's Profitability Ratios RPRX's Asset Turnover Ratio RPRX's Dividend Growth
RPRX's Roe RPRX's Valuation Ratios RPRX's Financial Strength Ratios RPRX's EBITDA Growth
RPRX's Roa RPRX's Inventory Turnover Ratio RPRX's Growth Rates RPRX's Dividend Comparisons


Companies with similar EBITDA Margin in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry EBITDA MarginDec 31 2023 MRQ EBITDADec 31 2023 MRQ Revenue
Revance Therapeutics Inc   192.96 %$ 134.686 $ 69.799 
Royalty Pharma Plc  128.31 %$ 764.841 $ 596.068 
Siga Technologies Inc  79.85 %$ 93.006 $ 116.481 
Prestige Consumer Healthcare Inc   58.45 %$ 164.795 $ 281.938 
United Therapeutics Corporation  52.74 %$ 324.200 $ 614.700 
Catalyst Pharmaceuticals Inc   50.51 %$ 55.850 $ 110.568 
Vertex Pharmaceuticals Inc  47.50 %$ 1,196.000 $ 2,517.700 
Protagonist Therapeutics inc   45.97 %$ 27.583 $ 60.000 
Johnson and Johnson  41.99 %$ 5,682.000 $ 13,532.000 
Zoetis Inc   37.73 %$ 835.000 $ 2,213.000 
Regeneron Pharmaceuticals Inc   37.24 %$ 1,278.900 $ 3,434.300 
Harmony Biosciences Holdings inc   36.35 %$ 61.244 $ 168.472 
Bristol myers Squibb Company  36.05 %$ 4,138.000 $ 11,477.000 
Ironwood Pharmaceuticals inc   33.93 %$ 39.882 $ 117.553 
Eli Lilly And Company  30.97 %$ 2,896.500 $ 9,353.400 
Bausch Health Companies Inc   29.03 %$ 699.000 $ 2,408.000 
Jazz Pharmaceuticals Plc  28.76 %$ 291.051 $ 1,011.935 
Corcept Therapeutics Inc  27.61 %$ 37.380 $ 135.405 
Abbott Laboratories  27.02 %$ 2,767.000 $ 10,241.000 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com